doxorubicin + paclitaxel + cyclophosphamide + methotrexate + fluorouracil

This is a **combination chemotherapy regimen** consisting of five cytotoxic drugs: doxorubicin (an anthracycline topoisomerase II inhibitor), paclitaxel (a microtubule-stabilizing agent), cyclophosphamide (an alkylating agent), methotrexate (a folate antimetabolite), and fluorouracil (an antimetabolite that targets thymidylate synthase). This regimen is not a widely named fixed combination product, but rather a protocol where these agents are administered sequentially or in combination, mainly in the management of **breast cancer**, especially in advanced/metastatic or high-risk early-stage settings. The rationale is to maximize cancer cell kill by combining agents with overlapping but distinct mechanisms of action and non-overlapping toxicities. Doxorubicin and paclitaxel are often given together (or sequentially) for their high efficacy but require caution due to cumulative cardiotoxicity and myelosuppression; cyclophosphamide, methotrexate, and fluorouracil (known as CMF) are a longstanding regimen themselves and are used in some protocols as a follow-on to doxorubicin + paclitaxel. The primary indication is **breast cancer**—especially as neoadjuvant, adjuvant, or metastatic therapy[1][3][7]. No single pharmaceutical company owns this regimen; it is an evidence-based protocol rather than a proprietary product.